glp-1 kidney outcomes news today receptor agonists' impact on cardio-renal and mortality in T2D with acute disease Association of glucagon-like peptide-1 receptor

The disease not only imposes significant physical and emotional burdens on patients but also results in substantial socioeconomic costs

and the fact that mal-absorption doesn't mean the same as no absorption

While GLP-1 medications are not psychiatric medications, their metabolic effects can influence mental health treatment plans

8,37 Secondary endpoints in STEP-HFpEF DM, including changes in 6-minute walk distance and body weight, also favoured semaglutide

For example, in the largest randomized trial to date (Sleep Apnea Cardiovascular Endpoints, SAVE), there was no difference in the incidence of strokes, heart attacks, composite cardiovascular mortality, or other cardiovascular endpoints between the PAP and usual-care groups [24]